

Daftar Pustaka

- ADA, 2013. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 36(1):67–74.
- Adlam, D., Evans, N., Malhotra, A., Midha, D., Rowley, F., Hutchings, D., *et al.*, 2012. Repeat percutaneous coronary revascularization: Indications and outcomes in a 'Real World' cohort, *Catheterization and Cardiovascular Interventions* 45(4).
- Agostini, M., Fino, C., Torchio, P., Vado, A., Bertora, M., Lugli, E., *et al.*, 2009. Impact of incomplete revascularization following OPCAB surgery. *J Card Surg* 24(6):650–656.
- Al-Gobari, M., El Khatib, C., Pillon, F., Gueyffier, F., 2013. Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. *BMC Cardiovascular Disorders* 13:52.
- Alhejily, W.A. & Ohman, E. M., 2012. Repeat Revascularization After PCI: Are We Reinventing the Wheel or Redefining Achilles' Heel?. *Circ Cardiovasc Interv.* 5:746–747.
- Ali, S. M., Sheikh, S., Ahmad, A., Moghis, U., 2015. Pre-Clinical and Phase I Clinical Study of Clopidogrel Lipid Suspension : Intravenously Injected Formulation Results in Faster Onset of Action and Dose-Dependent Inhibition of Platelet Aggregation. *J Pharmacol Clin Toxicol* 3(1):1039.
- Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., *et al.*, 2014. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. *J Am Coll Cardiol* 64(24):e139–e228.
- Anand, S. S., Islam, S., Rosengren, A., Franzosi, M. G., Steyn, K., Yusufali, A. H., *et al.*, 2008. Risk factors for myocardial infarction in women and men: Insights from the INTERHEART study. *Eur Heart J* 29(7):932–940.
- Andersson, C., Mérie, C., Jørgensen, M., Gislason, G. H., Torp-Pedersen, C., Overgaard, C., *et al.*, 2014. Association of β -Blocker Therapy With Risks of Adverse Cardiovascular Events and Deaths in Patients With Ischemic Heart Disease Undergoing Noncardiac Surgery. *JAMA Intern Med* 174(3):336–344.
- Andersson, C., Nielsen, M., Køber, L., Torp-pedersen, C., 2012. Association of Clopidogrel Treatment With Risk of Mortality and Cardiovascular Events Following Myocardial Infarction. *JAMA* 308:882–889.
- Ankam, J., Feldman, D. I., Blaha, M. J., Martin, S. S., 2014. Improving lipid control following myocardial infarction. *Curr Opin Cardiol* 29 (5):454–66.

- Bauer, T., Bouman, H. J., van Werkum, J. W., Ford, N. F., ten Berg, J. M., Taubert, D., 2011. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. *BMJ (Clinical Research Ed.)* 343:d4588.
- Beigel, R., Hod, H., Fefer, P., Asher, E., Novikov, I., Shenkman, B., *et al.*, 2011. Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. *Am J Cardiol* 107(3):339–342.
- Bernat, R., Szavits-Nossan, J., Trbović, A., Kapov-Svilicić, K., Sesto, I., Sipić, T., *et al.*, 2012. Relationship of genetic markers for atherosclerosis and long-term outcome after percutaneous coronary intervention with stenting. *Coll Antropol*, 36 (4):1385–90.
- Blicher, T. M., Hommel, K., Kristensen, S. L., Torp-Pedersen, C., Madsen, M., Kamper, a.-L., *et al.*, 2014. Benefit of Clopidogrel Therapy in Patients With Myocardial Infarction and Chronic Kidney Disease--A Danish Nation-Wide Cohort Study. *J Am Heart Assoc.* 3(4):e001116–e001116.
- Cambria-Kelly, J. A. & Gandhi, P. J., 2002. Possible mechanisms of aspirin resistance, *J Thromb Thrombolysis* 13(1):49–56.
- Cannon, C. P., Brindis, R. G., Chaitman, B. R., Cohen, D. J., Cross, J. T., Drozda, J. P., *et al.*, 2013. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association. *Circulation* 127(9):1052–89.
- CAPRIE, 1996. A randomised , blinded , trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 348:1329–1339.
- Chan, M. Y., Tan, K., Tan, H.-C., Huan, P.-T., Li, B., Phua, Q.-H., *et al.*, 2012. polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. *Pharmacogenomics* 13(5):533–542.
- Charlot, M., Ahlehoff, O., Norgaard, M. L., Jørgensen, C. H., Sørensen, R., 2010. Annals of Internal Medicine Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use. *Ann Intern Med* 153(6):379.
- Choudhry, N. K., Avorn, J., Glynn, R. J., Antman, E. M., Schneeweiss, S., Toscano, M., *et al.*, 2011. Full Coverage for Preventive Medications after Myocardial Infarction. *N Engl J Med* 365(22):2088–2097.
- Cowper, P. a., Pan, W., Anstrom, K. J., Kaul, P., Wallentin, L., Davidson-Ray, L., *et al.*, 2015. Economic Analysis of Ticagrelor Therapy From a U.S. Perspective. *J Am Coll Cardiol* 65(5):465–476.

- Dean, L., 2011. Clopidogrel Therapy and CYP2C19 Genotype Drug : Clopidogrel. *Medical Genetics Summaries* 19(2).
- Dharma, S., Juzar, D. A., Firdaus, I., Soerianata, S., Wardeh, A. J., Jukema, J. W., 2012. Acute myocardial infarction system of care in the third world. *Netherlands Heart Journal* 20(6):254–259.
- Dhillon, S., 2015. Ticagrelor: A Review of Its Use in Adults with Acute Coronary Syndromes. *Am J Cardiovasc Drugs* 15(1):51–68.
- Dobesh, P. P. & Oestreich, J. H., 2014. Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. *Pharmacotherapy* 34(10):1077–1090.
- FDA, 2010. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available from: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm> [Accessed 29 May 2015].
- Ferguson, A. D., Dokainish, H., Lakkis, N., 2008. Aspirin and Clopidogrel Response Variability. *Tex Heart Inst J* 35(3):313–320.
- Fintel, D. J., 2012. Oral antiplatelet therapy for atherothrombotic disease: Overview of current and emerging treatment options, *Vascular Health and Risk Management* 8(1):77–89.
- Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., *et al.*, 2014. Heart Disease and Stroke Statistics - 2014 Update: A report from the American Heart Association. *Circulation* 129(3):e28-e292
- Gössl, M., Faxon, D. P., Bell, M. R., Holmes, D. R., Gersh, B. J., 2012. Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease. *Circ Cardiovasc Interv* 5(4):597-604.
- Hayasaka, M., Takahashi, Y., Nishida, Y., Yoshida, Y., Hidaka, S., Asai, S., 2013. Comparative effect of clopidogrel plus aspirin and aspirin monotherapy on hematological parameters using propensity score matching. *Vascular Health and Risk Management* 9(1):65–90.
- Hayes K.R and Applegate R.J. *et al*, 2010. Target Lesion Revascularization after Bare-metal or Drug-eluting Stents: Clinical Presentations and Outcomes. *J Invasive Cardiol.* 22(6):266-70
- Ho, P. M., Bryson, C. L., Rumsfeld, J. S., 2009. Medication adherence: Its importance in cardiovascular outcomes. *Circulation* 119 (23):3028–3035.
- Ho, P. M., Maddox, T. M., Wang, L., Fihn, S. D., Jesse, R. L., Peterson, E. D., *et al.*, 2009. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. *JAMA* 301(9):937–944.

- Horenstein, R. B., Madabushi, R., Zineh, I., Yerges-Armstrong, L. M., Peer, C. J., Schuck, R. N., *et al.*, 2014. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. *J Clin Pharmacol* 54(8):865–873.
- Husted, S. & van Giezen, J. J. J., 2009. Ticagrelor: The First Reversibly Binding Oral P2Y₁₂ Receptor Antagonist. *Cardiovascular Therapeutics* 27(4):259–274.
- Ike, A., Shirai, K., Nishikawa, H., Iwata, A., Yahiro, E., Sugihara, M., *et al.*, 2014. Associations between different types of hypoglycemic agents and the clinical outcome of percutaneous coronary intervention in diabetic patients—From the FU-Registry. *J Cardiol* 65(5):390–396.
- Isshiki, T., Kimura, T., Ueno, T., Nakamura, M., Igarashi, K., Yokoi, H., *et al.* 2012., CLopidogrel Trial in Patients With Elective Percutaneous Coronary Intervention for Stable ANgina and Old Myocardial Infarction (CLEAN). *Int Heart J* 53 (2):91–101.
- Juwana, Y. B., Wirianta, J., Ottervanger, J. P., Dambrink, J. H. E., Van 't Hof, a. W. J., Gosselink, a. T. M., *et al.*, 2009. Primary coronary intervention for ST-elevation myocardial infarction in Indonesia and the Netherlands: A comparison. *Neth Heart J* 17(11):418–421.
- Kang, H.-J., Clare, R. M., Gao, R., Held, C., Himmelmann, A., James, S. K., *et al.*, 2015. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. *Am Heart J* 169(6):899–905.
- Karaźniewicz-Łada, M., Danielak, D., Burchardt, P., Kruszyna, Ł., Komosa, A., Lesiak, M., *et al.*, 2014. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. *Clin Pharmacokinet* 53(2):155–164.
- Kelly, D. J., Gershlick, T., Witzenbichler, B., Guagliumi, G., Fahy, M., Dangas, G., *et al.*, 2011. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. *Am Heart J* 162(4):663–70.
- Kim, H. S., Chang, K., Koh, Y. S., Park, M. W., Choi, Y. S., Park, C. S., *et al.*, 2013. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. *Circ Cardiovasc Genet.* 6(5):514–521.
- Kip, K. E., Hollabaugh, K., Marroquin, O. C., Williams, D. O., 2008. The Problem With Composite End Points in Cardiovascular Studies. The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention. *J Am Coll Cardiol* 51(7):701–707.

- Klungel, O. H., Heckbert, S. R., De Boer, A., Leufkens, H. G. M., Sullivan, S. D., Fishman, P. a., *et al.*, 2002. Lipid-lowering drug use and cardiovascular events after myocardial infarction. *Ann Pharmacother* 36(5):751–757.
- Kumar, A. & Cannon, C. P., 2009. Acute Coronary Syndromes: Diagnosis and Management, Part I. *Mayo Clin Proc.* 84(10):17–938.
- Laslett, L. J., Alagona, P., Clark, B. a., Drozda, J. P., Saldivar, F., Wilson, S. R., *et al.*, 2012. The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues: A report from the american college of cardiology. *J Am Coll Cardiol* 60(25):S1–S49.
- Law, M. R., Morris, J. K., Wald, N. J., 2009. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* 338:b1665.
- Leander, K., Wiman, B., Hallqvist, J., Andersson, T., Ahlbom, A., de Faire, U., 2007. Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP). *Eur J Cardiovasc Prev Rehabil* 14(4):532–537.
- Lee, M. G., Jeong, M. H., Ahn, Y., Chae, S. C., Hur, S. H., Hong, T. J., *et al.*, 2009. Comparison of clinical outcomes following acute myocardial infarctions in hypertensive patients with or without diabetes. *Korean Circ J* 39(6):243–50.
- Lee, M. G., Jeong, M. H., Ahn, Y., Chae, S. C., Hur, S. H., Hong, T. J., *et al.*, 2012. Additive impact of diabetes mellitus on patients with metabolic syndrome and acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Int J Cardiol* 157(2):283–285.
- Lee, M. G., Jeong, M. H., Lee, K. H., Park, K. H., Sim, D. S., Yoon, H. J., *et al.*, 2012. Prognostic impact of diabetes mellitus and hypertension for mid-term outcome of patients with acute myocardial infarction who underwent percutaneous coronary intervention, *Journal of Cardiology* 60(4):257–263.
- Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. a., Cercek, B., *et al.*, 2011. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. *J Am Coll Cardiol* 58(24):2550-83.
- Li, Q., Yu, X., He, J., Gao, Y., Zhang, X., Wu, C., *et al.* 2014., The Relationship Between Revascularization Extent and the Long-term Prognosis of Patients With Stable Angina Pectoris and Three-Vessel Disease Treated by Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents. *Clin. Cardiol.* 575

- Lindholm, D., Varenhorst, C., Cannon, C. P., Harrington, R. a., Himmelmann, a., Maya, J., *et al.*, 2014. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. *Eur Heart J* 35(31):2083–2093.
- Ma, Q. & Lu, A. Y. H., 2011. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. *Pharmacol Rev* 63(2):437-459.
- Mason, P. J., Jacobs, A. K. & Freedman, J. E., 2005. Aspirin resistance and atherothrombotic disease. *J Am Coll Cardiol* 46(6):986–993.
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., *et al.*, 2014. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. *N Engl J Med* 371(23):2155-2166.
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., *et al.* 2014. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents, *N Eng J Med*, 371 (23): 2155–66
- McConnell, K. J., Olson, K. L., Delate, T., Merenich, J. a, 2009. Factors associated with recurrent coronary events among patients with cardiovascular disease. *Pharmacotherapy* 29(8):906–913.
- Meliga, E., Fiorina, C., Valgimigli, M., Belli, R., Gagnor, A., Sheiban, I., *et al.*, 2011. Early Angio-Guided Complete Revascularization versus Culprit Vessel PCI Followed by Ischemia-Guided Staged PCI in STEMI Patients with Multivessel Disease. *J Interven Cardiol* 24(6):535–541.
- Mendis, S., Abegunde, D., Yusuf, S., Ebrahim, S., Shaper, G., Ghannem, H., *et al.*, 2005. WHO study on Prevention of REcurrences of Myocardial Infarction And Stroke (WHO-PREMISE). *Bulletin of the World Health Organization* 83(11):820–828.
- Mendis, S., Puska, P., Norrving, B., 2011. Global atlas on cardiovascular disease prevention and control. *World Health Organization*, pp. 2–14.
- Mendis, S., Thygesen, K., Kuulasmaa, K., Giampaoli, S., Mahonen, M., Blackett, K. N., *et al.*, 2011. World Health Organization definition of myocardial infarction: 2008-09 revision. *International Journal of Epidemiology* 40(1):139–146.
- Nabel, E. G., Braundwald, E., 2012. A tale of coronary artery disease and myocardial infarction. *N Eng J Med* 366(1):54–63.
- Nakatani, D., Sakata, Y., Suna, S., Usami, M., Matsumoto, S., Shimizu, M., *et al.*, 2013. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. *Circ J* 77(2):439–46.

- O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Mina, K., Lemos, J. A. De, *et al.*, 2013. Foundation / American Heart Association Task Force on Practice Guidelines ACCF / AHA Guideline 2013 ACCF / AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary A Report of the American College of Cardiology Foundation. *Circulation* 127:529–555.
- Picariello, C., Lazzeri, C., Attanà, P., Chiostri, M., Gensini, G. F., Valente, S., 2011. The impact of hypertension on patients with acute coronary syndromes. *International Journal of Hypertension* 563657.
- Presley, B., 2013. Ticagrelor: Antagonis P2Y12. *Medikamen* (20).
- Radovanovic, D., Erne, P., Schilling, J., Nosedà, G., Gutzwiller F on behalf of the AMIS Plus Investigators, 2005. Association of dyslipidemia and concomitant risk factors with in-hospital mortality in acute coronary syndrome in Switzerland. *HeartDrug* 5:131–139.
- Roden, D. M. & Stein, C. M., 2009. Clopidogrel and the concept of high-risk pharmacokinetics. *Circulation* 119(16):2127–2130.
- Ruiz-Nodar, J. M., Marín, F., Hurtado, J. A., Valencia, J., Pinar, E., Pineda, J., *et al.*, 2008. Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation. *J Am Coll Cardiol* 51(8):818–825.
- Saito, D., Shiraki, T., Oka, T., Kajiyama, A., Takamura, T., 2002. Risk factors indicating recurrent myocardial infarction after recovery from acute myocardial infarction., *Circ J* 66(10):877–880.
- Samsky, M. D., Patel, C. B., Dewald, T. a., Smith, A. D., Felker, G. M., Rogers, J. G., *et al.*, 2013. Cardiohepatic interactions in heart failure: An overview and clinical implications. *J Am Coll Cardiol* 61(24):2397–2405.
- Schroeder, W. S., Ghobrial, L., Gandhi, P. J., 2006. Possible mechanisms of drug-induced aspirin and clopidogrel resistance. *Journal of Thrombosis and Thrombolysis* 22(2):139–150.
- Sethi, A., Bahekar, A., Bhuriya, R., Bajaj, A., Kovacs, D., Ahmed, A., *et al.*, 2012. Drug-eluting stents versus bare metal stents in ST elevation myocardial infarction at a follow-up of three years or longer: A meta-analysis of randomized trials. *Exp Clin Cardiol* 17(4):169–74.
- Sharma, R. K., Reddy, H. K., Singh, V. N., Sharma, R., Voelker, D. J., Bhatt, G., 2009. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. *Vascular Health and Risk Management* 5:965–972.
- Simoons, M. L. & Windecker, S., 2010. Chronic stable coronary artery disease: drugs vs. revascularization. *Eur Heart J* 31(5):530–541.

- Snoep, J. D., Hovens, M. M. C., Eikenboom, J. C. J., van der Bom, J. G., Jukema, J. W., Huisman, M. V., 2007. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. *Am Heart J* 154(2):221–231.
- Song, P. S., Kim, D. K., Seo, G. W., Kim, K. H., Seol, S. H., Yang, J. H., *et al.*, 2014. Spironolactone lowers the rate of repeat revascularization in acute myocardial infarction patients treated with percutaneous coronary intervention. *Am Heart J* 168(3):346–353 e3.
- Song, P. S., Kim, D. K., Seo, G. W., Kim, K. H., Seol, S. H., Yang, J. H., *et al.*, 2014. Spironolactone lowers the rate of repeat revascularization in acute myocardial infarction patients treated with percutaneous coronary intervention. *Am Heart J* 168 (3) 346–353
- Steg, P. G., James, S., Harrington, R. a., Ardissino, D., Becker, R. C., Cannon, C. P., *et al.*, 2010. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. *Circulation* 122(21):2131–2141.
- Stolker, J. M., Cohen, D. J., Kennedy, K. F., Pencina, M. J., Lindsey, J. B., Mauri, L., *et al.*, 2012. Repeat Revascularization After Contemporary Percutaneous Coronary Intervention: An Evaluation of Staged, Target Lesion, and Other Unplanned Revascularization Procedures During the First Year. *Circ Cardiovasc Interv.* 5 (6):772–782.
- Takahashi, M., Saito, T., Ito, M., Tsukada, C., Katono, Y., Hosono, H., *et al.*, 2014. Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation. *The Pharmacogenomics Journal* 15(1):26–32.
- Tantry, U. S., Bliden, K. P., Wei, C., Storey, R. F., Armstrong, M., Butler, K., *et al.*, 2010. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: The ONSET/OFFSET and RESPOND genotype studies. *Circ Cardiovasc Genet.* 3(6):556–566.
- Teng, R., 2015. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. *Clin Pharmacokinet* 54:1125–1138.
- Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., *et al.*, 2012. Third Universal Definition of Myocardial Infarction. *J Am Coll Cardiol* 60(16):1581–1598.
- Tolstrup, J. S., Hvidtfeldt, U. a, Flachs, E. M., Spiegelman, D., Heitmann, B. L., Bälter, K., *et al.*, 2014. Smoking and risk of coronary heart disease in younger, middle-aged, and older adults. *Am J Public Health.* 104(1):96–102.

- Tourmousoglou, C. E. & Rokkas, C. K., 2008. Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence. *Cardiovascular & Hematological Agents in Medicinal Chemistry* 6(4):312–322.
- Tuppin, P., Neumann, A., Danchin, N., De Peretti, C., Weill, A., Ricordeau, P., *et al.*, 2010. Evidence-based pharmacotherapy after myocardial infarction in France: Adherence-associated factors and relationship with 30-month mortality and rehospitalization. *Archives of Cardiovascular Diseases* 103(6-7):363–375.
- Ueshima, H., Sekikawa, a., Miura, K., Turin, T. C., Takashima, N., Kita, Y., *et al.*, 2008. Cardiovascular Disease and Risk Factors in Asia: A Selected Review. *Circulation* 118(25):2702–2709.
- Wallentin, L., 2009. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. *Eur Heart J* 30(16):1964–1977.
- Wallentin, L., Becker, R. C., Buday, A., Cannon, C. P., Emanuelsson, H., Held, C., *et al.*, 2009. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. *N Eng J Med* 361(11):1045–1057.
- Wihanda, D., Alwi, I., Yamin, M., Shatri, H., Mudjaddid, E., 2015. Factors Associated with In-stent Restenosis in Patients Following Percutaneous Coronary Intervention. *Acta Med Indones-Indones J Intern Med* 209–215.
- Wong, N. D., 2014. Epidemiological studies of CHD and the evolution of preventive cardiology., *Nat Rev Cardiol* 11(5):276–89.
- Wu, X., Lv, S., Yu, X., Yao, L., Mokhlesi, B. and Wei, Y. 2015. Treatment of OSA reduces the risk of repeat revascularization after percutaneous coronary intervention. *Chest* 147 (3):708–718.
- Yasmina, A., de Boer, A., Klungel, O. H., Deneer, V. H., 2014. Pharmacogenomics of oral antiplatelet drugs. *Pharmacogenomics* 15(4):509–28.
- Yusuf, I., Djojosebroto, M. W., Ikawati, R., Lum, K., Kaneko, A., Marzuki, S., 2003. Ethnic and geographical distributions of CYP2C19 alleles in the populations of Southeast Asia, *Advances in Experimental Medicine and Biology* 531:37–46.
- Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G., Fox, K. K., 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 345:494-502.

- Zellweger, M. J., Fahrni, G., Ritter, M., Jeger, R. V., Wild, D., Buser, P., *et al.* 2014. Prognostic value of 'routine' cardiac stress imaging 5 years after percutaneous coronary intervention: The prospective long-term observational BASKET (Basel Stent Kosteneffektivit??ts Trial) LATE IMAGING study. *J Am Coll Cardiol Intv* 7 (6):615–621
- Zhou, Y. H., Wei, X., Lu, J., Ye, X. F., Wu, M. J., Xu, J. F., *et al.*, 2012. Effects of Combined Aspirin and Clopidogrel Therapy on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. *PLoS ONE* 7(2):e31642.
- Zhuang, X.-D., Long, M., Li, C.-L., Hu, C.-H., Du, Z.-M. and Liao, X.-X. 2014. Efficacy and safety of low-dose clopidogrel after 12-month dual antiplatelet therapy for patients having drug-eluting stent implantation. *J Thorac Dis* 6 (5):459–65